entertainment -WSS

entertainment

author：fashion 2025-08-12 08:29:38 - browse：8

Jennifer Doudna Feng Zhang CRISPR — CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

The revolution started in silence.

Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Being 'nonadherent' patient made me a more empathetic doctor

WSS

FDA warns medical device makers about rise in fabricated data

Flagship Pioneering startup Sonata Therapeutics lays off 21

Drug cartel violence flares in western Mexico after vigilante leader's killing

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

As AI regulations shape up, health tech startups beg for clarity

knowledge

entertainment

focus

23andMe had bad news about my health. I wish a person had delivered it

Researchers tackle phage therapy hurdles for wider adoption

Supreme Court strikes down use of affirmative action

A new drug could help frostbite victims avoid its ravages

Novavax promises a turnaround & Lilly roils the obesity market

Drug cartel violence flares in western Mexico after vigilante leader's killing

Duchenne breakthrough therapy leaves behind pioneering families

A letter from the executive editor: The 2023 STATUS List

Medical records are filled with copy

Crowdfunding for unproven stem cell procedures spreads misinformation

leisure time

Hubble vs. James Webb telescope images: See the difference

Use doctors trained outside the U.S. to ease the physician shortage

Congress may force more Covid

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Reporting on presidential health from Reagan to Trump and Biden

hotspot

focus

focus

explore